Recombinant humanized monoclonal antibody injection against human vascular endothelial growth
factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd
Biological similar drugs. Its mechanism is to prevent VEGF from binding to its natural
receptor VEGFR, inhibit the proliferation and activation of vascular endothelial cells, and
play an anti angiogenesis and anti-tumor role by binding with VEGF. A randomized,
double-blind, single dose, parallel comparison of bevacizumab injection and Avastin is
planned The phase I clinical study on the similarity of pharmacokinetics and safety of
traditional Chinese medicine in healthy male volunteers aims to compare bevacizumab injection
with Avastin The similarity of pharmacokinetics, tolerance, safety and immunogenicity.